Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.91 -0.21%
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.66, $0.26 better than the analyst estimate of $0.40. Revenue for the quarter came in at $136.5 million versus the consensus estimate of $103.16 million.
GUIDANCE:
Halozyme Therapeutics sees FY2021 EPS of $1.85-$2.00, versus the consensus of $1.41. Halozyme Therapeutics sees FY2021 revenue of $425-445 million, versus the consensus of $404.6 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Red River Bancshares, Inc. (RRBI) Tops Q3 EPS by 7c
- Oppenheimer Holdings (OPY) Reports Q3 EPS of $1.81
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
